TABLE OF CONTENTS. 4. Formulation Opportunities Oral Reformulation Taste Masking MCD GROUP, LLC October

Similar documents
Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form

2/7/13. Andrea Rhodes, PharmD Undergraduate: Kansas State University and Wichita State University for prepharmacy

Aradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008

ADDITIONAL DRUG LISTING FOR MEDICARE & MEDI-CAL MEMBERS

For External Use Only. Should neither be swallowed. Nor injected

innovative products. faster to market. reliably supplied.

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

PHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004

Medication Administration Curriculum INSTRUCTOR S MANUAL. Name State Date

FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST

PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION

Chapter 7. Principles of Pharmacology

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

MEDICATION OR OTHER SUBSTANCE

OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS

N a s d a q : I N S Y

Smoking and Nicotine Replacement Therapy (NRT) Lec:5

MODULE 3 How to Administer Medication

MEDICATION OR OTHER SUBSTANCE

Medimetriks Highlights

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY

Pharmacy Prep. Qualifying Pharmacy Review

11:00-11:50 AM 8:00-8:50 AM

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Principals and dosage forms of pharmaceutics

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018

PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) TABLE 9 SURGICAL COSTS FOR MYRINGOTOMY IN U.S. Adenoidectomy and Tonsillectomy...

CHAPTER ONE: EXECUTIVE SUMMARY

<1151> Pharmaceutical Dosage Forms and <1152> Animal Drugs for Use in Animal Feeds

UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants

Drug Therapy Following Bariatric Surgery

Just the Basics: Pharmacology for the EMT

ORALLY DISINTEGRATING TABLETS: BRIDGING THE DIVIDE FOR COMPLIANCE

Ingredient Listing Qty. Unit NDC # Supplier

Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. C. Nopitsch-Mai London 1

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

Routes of drug administration

QUANTITY LIMIT CRITERIA

Medication Administration. By: Carolyn McCune RN, BSN, MSN, CRNP

Easy, fast and reliable!

PEDIATRIC PHARMACOTHERAPY

Chapter 7. National EMS Education Standard Competencies (1 of 5) National EMS Education Standard Competencies (2 of 5) Principles of Pharmacology

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Acorda Acquisition of Civitas Therapeutics. September 24, 2014

Electronic Prescription Service (EPS) dm+d and Prescribing Systems

Magellan Rx. A smarter approach to pharmacy benefits management

Q1 FY02/2014 Results

BDSI Corporate Overview

300 3PORTUGUESE 65M GLOBAL WHO WE ARE WE OFFER PORTUGUESE

Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM

Division 1 Introduction to Advanced Prehospital Care

P.L.E.A.S.E. transdermal protein delivery. DDP 2011, Miami

Medications: Non-Oral Administration Work Sheet

J.P. Morgan Healthcare Conference

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

Q3 18 Earnings Supplemental Slides

Egalet Corporate Presentation

Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors

Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University

ALLERGIES ARE OUT THERE.

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

Managing Your OTC Medications. A Pharmacy Guide to Self- Care

Chapter 7, Medication Administration Part 1 Principles and Routes of Medication Administration Caution: Administering medications is business Always

Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Merrill Lynch Healthcare Conference New York

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients

Products that contain medications that the FDA calls drugs will list Drug Facts on the label and may include:

Controlled Delivery of Biologics NBC 22 June 2009

Easy, fast and reliable!

Corium Investor Update 16 th Annual Needham Healthcare Conference

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

Cantor Global Healthcare Conference

BALCHEM CORPORATION. Q Investor Relations Presentation

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023

UPDATE Ohana QUEST Integration Medicaid

Shire plc. Matthew Emmens, CEO

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38

innovative products. faster to market. reliably supplied.

Is there codeine in pseudoephedrine

Irritable Bowel Syndrome - Pipeline Review, H2 2016

Part 1 Principles and Routes of Medication Administration

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

Travel Health: Selecting, Dosing, Storing & Administering Medications for Children

Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p.

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

UNIT 2 SOLID AND LIQUID DOSAGE FORMS

STRATTERA (Stra-TAIR-a)

Pharmaceutical Preparation For Internal Use

Transcription:

TABLE OF CONTENTS 1. Executive Summary... 9 Market Overview... 9 Drug Delivery Systems for Pediatrics... 10 Formulation Opportunities... 10 Specialty Pediatric Companies... 11 Product Licensing Opportunities... 11 2. Pediatric Market Overview... 12 Market Needs... 12 Therapeutic Needs... 13 Hypertension... 13 Hypercholesterolemia... 14 Diabetes... 15 Pain Management... 16 Anti-Infectives... 17 Respiratory / Allergy... 17 Attention Deficit Hyperactivity Disorder... 19 Epilepsy... 20 Market Size... 22 Key Therapeutic Areas... 25 CNS... 25 Allergies... 26 Asthma... 27 Infections... 28 3. Drug Delivery Systems for Pediatrics... 30 Marketed Products... 30 Dosage Forms... 38 Taste Masking... 38 Orally Disintegrating Dosage Forms... 39 Soft Chewable Delivery Systems... 42 Oral Liquid Delivery Systems... 44 Oral Mucosal Delivery Systems... 46 Transdermal Delivery Systems... 47 Topical Delivery Systems... 48 Nasal Drug Delivery... 49 Pulmonary Delivery Systems... 51 Parenteral and Device Technologies... 53 4. Formulation Opportunities... 54 Oral Reformulation... 54 Taste Masking... 57 3

Non-invasive Formulations... 58 5. Companies with Pediatric Focus... 59 Adamis Pharmaceuticals Corporation... 60 Aires Pharmaceuticals, Inc... 61 Arbor Pharmaceuticals, Inc... 62 Asklepion Pharmaceuticals, Inc.... 64 Centrix Pharmaceutical, Inc.... 66 Cornerstone Therapeutics, Inc.... 68 Curemark, LLC... 70 FSC Pediatrics, Inc... 71 InfaCare Pharmaceutical Corporation... 72 Lupin Pharmaceuticals, Inc... 73 Madeira Therapeutics... 74 McNeil Pediatrics... 75 Meritage Pharma, Inc... 76 Next Wave Pharmaceuticals, Inc.... 77 ParaPRO, LLC... 78 Pediapharm, Inc.... 79 Pernix Therapeutics Holdings, Inc.... 81 Reckitt Benckiser Pharmaceutical, Inc.... 82 Seaside Therapeutics, Inc... 85 Shionogi Pharma, Inc... 86 TaroPharma... 88 Teva Respiratory, LLC... 90 Tiber Laboratories, LLC... 92 Topaz Pharmaceuticals, Inc.... 93 TRx Pharma... 94 6. Drug Delivery Technologies for Pediatric Drugs... 95 Buccal Delivery Systems... 96 APTYS Pharmaceuticals... 97 Biodel, Inc... 98 BioDelivery Sciences International...100 Corium International, Inc....101 Fertin Pharma...102 NovaDel Pharma...104 Orexo AB...106 ULURU, Inc....108 Watson, Inc....110 Oral Delivery Systems...112 Acino Holding, Ltd....113 Akina, Inc....114 Alpex Pharma...116 Alte Biosciences, Inc....118 4

Aprecia Pharmaceuticals Company...119 Arx, LLC...120 Banner Pharmacaps...121 Capricorn Pharma, Inc....123 Catalent Pharma Solutions...125 CIMA Labs, Inc....128 Collegium Pharmaceutical, Inc....131 Dow Wolff Cellulosics...132 Egalet A/S...134 Ethypharm...135 Eurand, Inc....137 Eurand, Inc....139 ForTe BV...140 Grunenthal GmbH...142 HealthSport, Inc....143 IntelGenx Corporation...145 KV Pharmaceutical Company...146 Labtec Pharma...147 Lavipharm...149 Losan Pharma GmbH...150 LTS Lohmann...152 Meldex International, PLC...154 MonosolRx...157 NAL Pharmaceuticals, Ltd....159 Pharmafilm S.r.l...161 Physica Pharma...163 SPI Pharma Inc....164 Tris Pharma...166 Xel Pharmaceuticals, Inc....168 Taste Masking Technologies...169 Balchem Corporation...170 Cambrex Corporation...171 Ethypharm...172 Eurand, Inc....173 ForTe BV...175 Oralance Pharma...177 Nasal Technologies...179 Ikano Therapeutics, Inc....180 OptiNose...182 Dermal Delivery Technologies...184 Altea Therapeutics...185 Foamix, Ltd....187 ForTe BV...190 Intercell...192 5

nanobiosciences, LLC...194 Pantec Biosolutions...196 Quinnova Pharmaceuticals, Inc....197 TransPharma Medical...198 Zosano Pharma...200 7. Product Licensing Opportunities...202 Albuterol Dry Powder Inhaler...203 Allergy Chewing Gum...204 Atopic Dermatitis Treatment...205 Atopiclair TM Cream...206 CRO-PED for Pediatric Diarrhea...208 Children s Dietary Supplement...209 Ciprofloxacin Otic Solution...210 Cough/Cold Pediatric Formulations...211 Decongestant Cream Stick...213 Decongestant Patch...214 Fever Cooling Patch...215 Foam-Based Dermatology Products...216 Foam-Based Products for Infants...218 GastroGard-R for Rotavirus...220 Hedrin TM for the Treatment of Head Lice...222 Human Growth Hormone Nasal Spray...224 Insect Repellent Patch...225 Insecticide-Free Head Lice Treatment...226 Liposomal Amikacin Formulation...227 Long-acting Somatropin Injection...228 Moisturizing Cream for Dermatitis...230 Nasal Somatropin Formulation...231 NeoCeram TM Skin Barrier Emulsion...232 Novel Head Lice Formulation...234 Once-weekly Injectable Somatropin...236 Oral Film Formulation of Prednisolone...238 Oral Rotavirus Thin Film Product...239 Orally Disintegrating Acetaminophen Formulations...240 Orally Disintegrating Allergy Products...241 Pediatric Pain Formulations...242 Peptide for Chronic Middle Ear Infections...243 Sinlice, Pediculicide Treatment...244 Site-Specific Otitis Media Treatment...246 Sustained Release Somatropin Injection...247 Teething Gel for Babies...248 Zinc Oxide Spray...250 6

INDEX OF TABLES Table 1: Pediatric Age Related Subgroups... 13 Table 2: Antihypertensives Granted Pediatric Exclusivity... 14 Table 3: Cholesterol Drugs Granted Pediatric Exclusivity... 15 Table 4: Diabetes Products Used in Pediatrics... 15 Table 5: Pain Medications Granted Pediatric Exclusivity... 16 Table 6: Emerging Technologies for Antibiotics... 17 Table 7: Leading Respiratory/Allergy Products for Pediatrics... 18 Table 8: ADHD Medications for Pediatrics... 19 Table 9: Drugs Approved for Epilepsy... 20 Figure 1: US Prescription Pediatric Market, 2009... 22 Table 10: Sales of 25 Drugs Commonly Prescribed to Pediatrics... 23 Table 11: Sales of Leading Pediatric-Focused Products, 2009... 24 Table 12: Sales of Leading ADHD Drugs, 2009... 26 Table 13: Sales of Leading Prescription Allergy Drugs, 2009... 26 Table 14: Sales of Leading Asthma Drugs, 2009... 27 Table 15: Pediatric Oral Antibiotic Market... 28 Table 16: DDS Products Approved for Pediatric Use... 31 Table 17: OTC DDS Products for Pediatrics... 36 Table 18: Key Players in Taste Masking... 39 Table 19: ODT Technology Summary... 40 Table 20: Key Players in ODT Market... 40 Table 21: Oral Film Technology Summary... 41 Table 22: Key Players in Oral Film Market... 41 Table 23: ODD Pipeline Products for Pediatrics... 42 Table 24: Advantages of Chewable Dosage Forms... 43 Table 25: Soft Chewable Delivery Systems... 43 Table 26: Liquid Drug Delivery Technologies... 44 Table 27: Liquid Pediatric Products in Development... 45 Table 28: Key Players in Buccal Delivery... 46 Table 29: Transdermal Pediatric Products... 47 Table 30: Transdermal Pipeline for Pediatrics... 48 Table 31: Topical Pediatric Pipeline... 49 Table 32: Nasal Pipeline Products Applicable to Pediatrics... 50 Table 33: Pulmonary Pipeline for Pediatrics... 51 Table 34: Parenteral DDS Pediatric Pipeline... 53 Table 35: Pediatric Drug Candidates for Oral Reformulation... 54 Table 36: Taste Masking Development Opportunities... 57 Table 37: Non-invasive Reformulation Opportunities... 58 Table 38: Arbor Product Pipeline... 62 Table 39: Asklepion Pipeline... 65 Table 40: Pediatric Products of Centrix... 66 Table 41: Therapeutic Targets of Centrix... 67 7

Table 42: Cornerstone Products Prescribed to Pediatrics... 68 Table 43: Madeira Product Pipeline... 74 Table 44: McNeil s Pediatric Product Developments... 75 Table 45: NextWave Pipeline Products... 77 Table 46: Pediapharm Pipeline... 79 Table 47: Marketed Products by Reckitt Benckiser... 82 Table 48: Pediatric Products Marketed by Shionogi... 86 Table 49: Shionogi Pediatric Pipeline... 86 Table 50: NonSpil OTC Products... 88 Table 51: Rx Products Marketed by Taro... 89 Table 52: Teva s Key Products for Pediatrics... 90 Table 53: Tiber Laboratories Product Portfolio... 92 Table 54: VIAdel Pipeline... 98 Table 55: NovaDel Pipeline...104 Table 56: Orexo s Sublingual Pipeline...106 Table 57: Alpex Pipeline...116 Table 58: Marketed Zydis Products...126 Table 59: Catalent Product Pipeline...126 Table 60: Products Developed by CIMA...129 Table 61: Ethypharm s ODT Products...135 Table 62: Eurand s ODT Products...137 Table 63: HealthSport Products...143 Table 64: Labtec Products...147 Table 65: LTS Wafer Systems...152 Table 66: Meldex DDS Pipeline...155 Table 67: MonosolRx Pipeline...157 Table 68: Malt-o-Fast Comparative Data...161 Table 69: Tris Product Pipeline...166 Table 70: Products Containing Microcaps Technology...173 Table 71: NODS Pipeline...177 Table 72: OptiNose Pipeline...182 Table 73: PassPort TM Product Pipeline...185 Table 74: ViaDerm Pipeline...198 Table 75: Foamix Pipeline Products...216 8